TNF Pharmaceuticals sets date for 2024 annual meeting

TNF Pharmaceuticals, Inc., a company specializing in in vitro and in vivo diagnostic substances, has announced the scheduling of its 2024 Annual Meeting of Stockholders for November 25, 2024. The record date for stockholders entitled to vote at the meeting has been established as the close of business on October 18, 2024.

This announcement, made on Monday, follows the company's decision on September 20 to change the meeting date, which now deviates by more than 30 days from the previous year's annual meeting. As a result, the company has outlined a new deadline for stockholder proposals and nominations.

Stockholders aiming to include a proposal in the proxy materials for the upcoming annual meeting must submit their proposals by October 3, 2024. This deadline is in accordance with Rule 14a-8 under the Securities Exchange Act of 1934 and aligns with the company's timeline for preparing and distributing proxy materials.

Furthermore, stockholders who wish to nominate director candidates or propose business outside of Rule 14a-8 must also submit their written notice by October 3, 2024. These submissions must adhere to the requirements detailed in the company's amended and restated Bylaws to be considered at the annual meeting.

In compliance with the universal proxy rules, stockholders planning to solicit proxies for director nominees other than those proposed by the company are required to provide notice by October 3, 2024, which includes the necessary information as per Rule 14a-19 under the Exchange Act.

In other recent news, TNF Pharmaceuticals has made significant strides in its financial and operational strategies. The company has altered the rights of its preferred stockholders, modifying the method for calculating the issuance of additional preferred stock for dividend payments.

This amendment was made effective immediately upon filing with the Secretary of State of Delaware. Additionally, TNF Pharmaceuticals has expanded its authorized shares of common stock from 16,666,666 to a substantial 250,000,000, providing greater flexibility for future financial operations.

TNF Pharmaceuticals also announced its rebranding, reflecting its focus on developing therapies targeting TNF-alpha, and will now trade under the new symbol "TNFA" on the Nasdaq Capital Market. The company is progressing to mid-stage clinical trials with its leading drug candidate, MYMD-1®, an orally administered TNF-alpha inhibitor. Morison Cogen LLP has been appointed as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.